BIIB Technical Analysis
As of date:2/24/2021
BIIB stock price:282.74
BIIB 50 DMA:263.58
BIIB 200 DMA:273.42
BIIB MACD (200-50):9.84
BIIB RSI:72.36
Extremely
Overbought
Overbought/Oversold RSI Range
RSI Indicator (Relative Strength Index)72.36
Extremely
Oversold

Also see:
BIIB Market Cap History
BIIB Shares Outstanding History
BIIB YTD Return

Try ChartSweeps today
Quotes delayed 20 minutes
Get Free SEC filing alerts for BIIB:
BIIB SEC Filing Email Alerts ServiceExternal link

Best Buy Breaks Below 200-Day Moving Average - Notable for BBY
just posted


FLTB Crosses Below Key Moving Average Level
2 minutes ago


IBDS Crosses Critical Technical Indicator
3 minutes ago


JMBS Crowded With Sellers
4 minutes ago


TAIL Crowded With Sellers
4 minutes ago


BSCP Crosses Critical Technical Indicator
4 minutes ago


Vanguard Short-Term Bond (BSV) Enters Oversold Territory
7 minutes ago


TIP Makes Notable Cross Below Critical Moving Average
7 minutes ago


SCHP Breaks Below 200-Day Moving Average - Notable for SCHP
8 minutes ago


CI Financial (CIX.CA) Shares Cross Below 200 DMA
22 minutes ago


CNST Crosses Below Key Moving Average Level
18 hours, 21 minutes ago


ATRI Makes Bullish Cross Above Critical Moving Average
18 hours, 38 minutes ago


SILV Crosses Above Key Moving Average Level
18 hours, 40 minutes ago


Fidelity National Information Services (FIS) Shares Cross Above 200 DMA
19 hours ago


ProShares Short Dow30 (DOG) Enters Oversold Territory
19 hours, 3 minutes ago


More Technical Analysis News

BIIB Technical AnalysisBIIB RSI
Biogen is a biopharmaceutical company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Co.'s main growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer's disease and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis; movement disorders, including Parkinson's disease; ophthalmology; and neuropsychiatry. Co.'s marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; and FUMADERM for the treatment of severe plaque psoriasis.

When researching a stock like Biogen, many investors are the most familiar with Fundamental Analysis — looking at a company's balance sheet, earnings, revenues, and what's happening in that company's underlying business. Investors who use Fundamental Analysis to identify good stocks to buy or sell can also benefit from BIIB Technical Analysis to help find a good entry or exit point. Technical Analysis is blind to the fundamentals and looks only at the trading data for BIIB stock — the real life supply and demand for the stock over time — and examines that data in different ways.
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks

10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
BIIB DMABIIB MACD
Video: Technical Analysis


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Biogen (BIIB) is categorized under the Healthcare sector; to help you further research Technical Analysis, below are some other companies in the same sector:

BMY Technical Analysis
BSX Technical Analysis
CAH Technical Analysis
CELG Technical Analysis
CNC Technical Analysis
COO Technical Analysis
DGX Technical Analysis
DHR Technical Analysis
DVA Technical Analysis
EW Technical Analysis
More Healthcare companies »

 

BIIB Technical Analysis | www.TechnicalAnalysisChannel.com | Copyright © 2019 - 2021, All Rights Reserved

Nothing in TechnicalAnalysisChannel.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.